SCHEMBL5136569

SCHEMBL5136569

CCCCN(Cc1ccc(O)cc1O)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
HDAC1 Q13547 3/20 0.41
TSHR P16473 4/20 0.39
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 5/20 0.37
HPGD P15428 4/20 0.37
HSD17B10 Q99714 4/20 0.37
CYP3A4 P08684 4/20 0.37
GAA P10253 3/20 0.37
MAPT P10636 3/20 0.37
USP2 O75604 1/20 0.37
GLA P06280 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TYR P14679 2/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137492 0.91 C5AR1 (0.42) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5074963 0.90 C5AR1 (0.43) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5072272 0.88 GAA (0.43) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5074977 0.88 C5AR1 (0.39) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5074785 0.87 C5AR1 (0.40) C5AR1HDAC1TSHR
SCHEMBL5136942 0.86 C5AR1 (0.46) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5136826 0.85 OPRM1 (0.47) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5135670 0.85 C5AR1 (0.43) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5136819 0.84 TSPO (0.40) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL650694 0.84 TSHR (0.51) C5AR1HDAC1TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed